Amy Gillespie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy Gillespie has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Alice Egerton
King's College London
7 shared publications Kyra-Verena Sendt
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
7 shared publications- Catherine J. Harmer
University of Oxford
6 shared publications Grant McQueen
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
6 shared publications- James Hunter MacCabe
King's College London
6 shared publications John Lally
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
5 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-8
Acute effects of AT1 receptor blockade on approach-avoidance of negative emotional faces
Recent evidence implicates the renin angiotensin system (RAS) in various cognitive markers of depression, including dysfunctional reward processing. Yet, it remains unknown whether these effects extend to other markers implicated in depression and its treatment, such as approach-avoidance motivations that reflect innate drives to approach reward and evade harm. We sought to examine the impact of acute losartan, an angiotensin type 1 (AT 1 ) receptor blocker, on the implicit approach-avoidance of facial expressions and checkerboard controls in healthy adults. In a randomized controlled trial, N = 68 healthy adults aged 18–50 (49 F/19 M) were administered a single 50 mg dose of losartan or placebo before completing an implicit Approach Avoidance Task (AAT) at drug-peak level. On the AAT, participants responded to color-filtered facial stimuli (happy, sad, angry, or neutral) and checkerboard controls using a joystick, and were instructed to pull all gray photos and push all brown photos as quickly as possible. Compared to placebo, losartan induced a significant avoidance bias for sad faces ( p = 0.027) and reduced avoidance of angry faces at trend level ( p = 0.085). This occurred without significant group differences on blood pressure, overall reaction time, accuracy, and approach-avoidance biases for other stimuli. The response pattern associated with AT 1 receptor blockade may counteract previously observed depressive tendencies, suggesting effects possibly consistent with antidepressant treatments. Our findings further highlight the RAS as a mechanistically relevant target for psychiatry, suggesting that AT 1 receptor antagonism may have relevance for treating depression and other emotional disorders characterized by aberrant motivational biases (Clincialtrials.gov ID: NCT06624904).
- 15 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-8
Open AccessAcute effects of AT1 receptor blockade on approach-avoidance of negative emotional faces
Recent evidence implicates the renin angiotensin system (RAS) in various cognitive markers of depression, including dysfunctional reward processing. Yet, it remains unknown whether these effects extend to other markers implicated in depression and its treatment, such as approach-avoidance motivations that reflect innate drives to approach reward and evade harm. We sought to examine the impact of acute losartan, an angiotensin type 1 (AT 1 ) receptor blocker, on the implicit approach-avoidance of facial expressions and checkerboard controls in healthy adults. In a randomized controlled trial, N = 68 healthy adults aged 18–50 (49 F/19 M) were administered a single 50 mg dose of losartan or placebo before completing an implicit Approach Avoidance Task (AAT) at drug-peak level. On the AAT, participants responded to color-filtered facial stimuli (happy, sad, angry, or neutral) and checkerboard controls using a joystick, and were instructed to pull all gray photos and push all brown photos as quickly as possible. Compared to placebo, losartan induced a significant avoidance bias for sad faces ( p = 0.027) and reduced avoidance of angry faces at trend level ( p = 0.085). This occurred without significant group differences on blood pressure, overall reaction time, accuracy, and approach-avoidance biases for other stimuli. The response pattern associated with AT 1 receptor blockade may counteract previously observed depressive tendencies, suggesting effects possibly consistent with antidepressant treatments. Our findings further highlight the RAS as a mechanistically relevant target for psychiatry, suggesting that AT 1 receptor antagonism may have relevance for treating depression and other emotional disorders characterized by aberrant motivational biases (Clincialtrials.gov ID: NCT06624904).
- Open Access
- 6 September 2026
- Published by Center for Open Science in PsyArXiv
Social anhedonia predicts behavioral differences in young people with and without depression during social exchange
The ability to form and sustain interpersonal relationships relies on the capacity to interpret social signals and update understanding of others’ behavior in dynamic contexts. Young adulthood is a critical period for refining these skills. Social learning and social reward responsivity have been implicated in depression, yet findings from social exchange studies remain mixed. Specifically, it remains unclear whether overall depressive symptom severity or specific symptoms such as anhedonia are most relevant to disrupted social decision-making.In a single-session online study, we examined social learning and generosity sensitivity in a UK population sample of young adults (18–24 years; n=553). Participants completed the Social Learning–Generosity (SL-Gen) task, a multi-round trust game paradigm designed to probe feedback-driven updating and behavioral adaptation to structured generosity conditions, alongside questionnaire measures of depression (PHQ-9) and social anhedonia (ACIPS).Depressive symptom severity was minimally associated with task performance; in contrast, greater social anhedonia and higher PHQ-9 anhedonia item scores were associated with differences in both evaluative updating and investment behavior. Specifically, individuals with greater social anhedonia showed lower initial investments, lower investments in higher generosity conditions, and smaller reductions in generosity ratings following unfair (loss-condition) interactions. Anhedonia was also associated with slightly flatter investment slopes in certain conditions.These findings suggest that anhedonia, rather than global depressive symptom severity, is linked to reduced sensitivity to negative social feedback. Task-based social learning measures may therefore help identify mechanistic subgroups within depression characterized by blunted social reward processing which may have utility for pinpointing treatment targets.
- 6 September 2026
- Published by Center for Open Science in PsyArXiv
Open AccessSocial anhedonia predicts behavioral differences in young people with and without depression during social exchange
The ability to form and sustain interpersonal relationships relies on the capacity to interpret social signals and update understanding of others’ behavior in dynamic contexts. Young adulthood is a critical period for refining these skills. Social learning and social reward responsivity have been implicated in depression, yet findings from social exchange studies remain mixed. Specifically, it remains unclear whether overall depressive symptom severity or specific symptoms such as anhedonia are most relevant to disrupted social decision-making.In a single-session online study, we examined social learning and generosity sensitivity in a UK population sample of young adults (18–24 years; n=553). Participants completed the Social Learning–Generosity (SL-Gen) task, a multi-round trust game paradigm designed to probe feedback-driven updating and behavioral adaptation to structured generosity conditions, alongside questionnaire measures of depression (PHQ-9) and social anhedonia (ACIPS).Depressive symptom severity was minimally associated with task performance; in contrast, greater social anhedonia and higher PHQ-9 anhedonia item scores were associated with differences in both evaluative updating and investment behavior. Specifically, individuals with greater social anhedonia showed lower initial investments, lower investments in higher generosity conditions, and smaller reductions in generosity ratings following unfair (loss-condition) interactions. Anhedonia was also associated with slightly flatter investment slopes in certain conditions.These findings suggest that anhedonia, rather than global depressive symptom severity, is linked to reduced sensitivity to negative social feedback. Task-based social learning measures may therefore help identify mechanistic subgroups within depression characterized by blunted social reward processing which may have utility for pinpointing treatment targets.
- Open Access
- 17 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Effects on hippocampal activity following novel 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study
Cognitive impairment is a common but under-treated feature of Major Depressive Disorder (MDD). Preclinical and early human studies suggest that 5-HT 4 receptor (5-HT 4 R) agonists rapidly improve learning and memory, consistent with this receptor’s role in hippocampal neuroplasticity. However, their effects in clinically depressed patients, remain unexplored. In this double-blind, randomised experimental medicine study, 52 right-handed, unmedicated individuals with MDD received 6–9 days of the 5-HT 4 R agonist PF-04995274 (15 mg, once daily) or placebo. Participants subsequently underwent fMRI scanning during a memory encoding task and completed behavioural measures of auditory verbal learning and spatial working memory. Compared to placebo, PF-04995274 significantly increased activity in the hippocampus (ROI analysis) in response to novel versus familiar images, particularly in the left hemisphere. Whole brain analysis also revealed greater activation in the left inferior parietal lobule, a key region for memory processing. In contrast with previous studies using the 5-HT 4 R agonist prucalopride, PF-04995274 had notably limited effects on behavioural measures of memory. The results demonstrate that short term 5-HT 4 R agonism enhances hippocampal and parietal activity during memory encoding in patients with depression. This replicates and extends previous findings in healthy volunteers using prucalopride, and is consistent with preclinical evidence establishing a key role for 5-HT 4 Rs in hippocampal-dependent learning and memory. This translational evidence supports a role for 5-HT 4 R activation in modulating memory-related brain circuits in MDD and previously identified beneficial effects of another 5-HT4 receptor agonist, prucalopride, on cognitive performance.
- 17 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessEffects on hippocampal activity following novel 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study
Cognitive impairment is a common but under-treated feature of Major Depressive Disorder (MDD). Preclinical and early human studies suggest that 5-HT 4 receptor (5-HT 4 R) agonists rapidly improve learning and memory, consistent with this receptor’s role in hippocampal neuroplasticity. However, their effects in clinically depressed patients, remain unexplored. In this double-blind, randomised experimental medicine study, 52 right-handed, unmedicated individuals with MDD received 6–9 days of the 5-HT 4 R agonist PF-04995274 (15 mg, once daily) or placebo. Participants subsequently underwent fMRI scanning during a memory encoding task and completed behavioural measures of auditory verbal learning and spatial working memory. Compared to placebo, PF-04995274 significantly increased activity in the hippocampus (ROI analysis) in response to novel versus familiar images, particularly in the left hemisphere. Whole brain analysis also revealed greater activation in the left inferior parietal lobule, a key region for memory processing. In contrast with previous studies using the 5-HT 4 R agonist prucalopride, PF-04995274 had notably limited effects on behavioural measures of memory. The results demonstrate that short term 5-HT 4 R agonism enhances hippocampal and parietal activity during memory encoding in patients with depression. This replicates and extends previous findings in healthy volunteers using prucalopride, and is consistent with preclinical evidence establishing a key role for 5-HT 4 Rs in hippocampal-dependent learning and memory. This translational evidence supports a role for 5-HT 4 R activation in modulating memory-related brain circuits in MDD and previously identified beneficial effects of another 5-HT4 receptor agonist, prucalopride, on cognitive performance.
- Open Access
- 28 May 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-10
Early effects of a novel 5-HT 4 R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study
Background: Selective serotonin reuptake inhibitors (SSRIs) are limited by inadequate response in a significant proportion of patients, slow onset, minimal cognitive benefit and side-effects. Preclinical studies suggest selective serotonin 4 receptor (5-HT 4 R) agonists may produce faster antidepressant effects via distinct mechanisms; however, there has been no experimental research in clinical populations to date. Aims: To test whether the novel 5-HT 4 R partial agonist PF-04995274 produces early behavioural and neural changes in emotional cognition similar to SSRIs in patients with unmedicated major depressive disorder (MDD). Method: In a double-blind, placebo-controlled trial, 90 participants with MDD were randomised to 7 days of PF-04995274 (15 mg), citalopram (20 mg) or placebo. Emotional processing was assessed using a behavioural facial expression recognition task and functional magnetic resonance imaging (fMRI) of implicit emotional face processing (days 6–9). Observer- and self-reported symptoms of depression were also measured at baseline and study end. Results: As anticipated, citalopram reduced relative accuracy and increased relative reaction time to identify negative faces, with corresponding changes in neural activity (reduced left amygdala activation to emotional faces and valence-specific shifts in cortical regions). In contrast, PF-04995274 produced no change in behavioural negative bias or amygdala activity but increased medial-frontal cortex activation across valences. While this was not a clinical trial, both active treatments demonstrated an early treatment response with reduced observer-rated depression severity relative to placebo; PF-04995274 also reduced self-reported depression, state anxiety and negative affect. Conclusions: PF-04995274 did not show the typical antidepressant profile of negative bias reductions observed with citalopram. Instead, it was associated with distinct increased medial-frontal activation during an emotional faces task, coupled with preliminary evidence of early clinical improvement, suggesting a potential alternative pathway for antidepressant effects. Findings support further clinical trials of 5-HT 4 R agonists and investigation of pro-cognitive and mood effects. Clinical trials registration number: NCT03516604.
- 28 May 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-10
Open AccessEarly effects of a novel 5-HT 4 R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study
Background: Selective serotonin reuptake inhibitors (SSRIs) are limited by inadequate response in a significant proportion of patients, slow onset, minimal cognitive benefit and side-effects. Preclinical studies suggest selective serotonin 4 receptor (5-HT 4 R) agonists may produce faster antidepressant effects via distinct mechanisms; however, there has been no experimental research in clinical populations to date. Aims: To test whether the novel 5-HT 4 R partial agonist PF-04995274 produces early behavioural and neural changes in emotional cognition similar to SSRIs in patients with unmedicated major depressive disorder (MDD). Method: In a double-blind, placebo-controlled trial, 90 participants with MDD were randomised to 7 days of PF-04995274 (15 mg), citalopram (20 mg) or placebo. Emotional processing was assessed using a behavioural facial expression recognition task and functional magnetic resonance imaging (fMRI) of implicit emotional face processing (days 6–9). Observer- and self-reported symptoms of depression were also measured at baseline and study end. Results: As anticipated, citalopram reduced relative accuracy and increased relative reaction time to identify negative faces, with corresponding changes in neural activity (reduced left amygdala activation to emotional faces and valence-specific shifts in cortical regions). In contrast, PF-04995274 produced no change in behavioural negative bias or amygdala activity but increased medial-frontal cortex activation across valences. While this was not a clinical trial, both active treatments demonstrated an early treatment response with reduced observer-rated depression severity relative to placebo; PF-04995274 also reduced self-reported depression, state anxiety and negative affect. Conclusions: PF-04995274 did not show the typical antidepressant profile of negative bias reductions observed with citalopram. Instead, it was associated with distinct increased medial-frontal activation during an emotional faces task, coupled with preliminary evidence of early clinical improvement, suggesting a potential alternative pathway for antidepressant effects. Findings support further clinical trials of 5-HT 4 R agonists and investigation of pro-cognitive and mood effects. Clinical trials registration number: NCT03516604.
- Open Access
- 19 May 2026
- Published by Center for Open Science in PsyArXiv
The Social Learning-Generosity (SL-Gen) Task: Redesigning the multi-round trust game paradigm to examine social learning and generosity sensitivity in young people
Social learning is important for societal functioning, and adolescence is a critical period for development and maintenance of social behaviors. Specifically, the ability to establish and maintain social interactions that are beneficial, while avoiding or removing oneself from social exchanges that are detrimental or harmful, is crucial for healthy interpersonal functioning. Beyond self-report measures, the multi-round trust game, a commonly used behavioral economics paradigm, has utility for elucidating differences in social decision-making between healthy and clinical populations. To more specifically probe the role of social learning and generosity sensitivity during social exchange in young people, we have designed a new task: the Social Learning-Generosity (SL-Gen) Task. Using versions of the multi-round trust game as a basis for the design, we have incorporated more environmentally realistic task components, including controlled gain, loss, and variable gain-loss generosity conditions. In a single-session online study, the present research investigated task behavior and task acceptability in individuals aged 18-24 from a United Kingdom census-based sample, as well as exploring task differences by self-reported trust and gender. While this task is sensitive to differences in self-reported trust and gender and behaves similarly to existing versions of the trust game with respect to these effects, it has added utility within mental health research and treatment contexts for characterizing social decision-making behavior in more detail using set generosity conditions.
- 19 May 2026
- Published by Center for Open Science in PsyArXiv
Open AccessThe Social Learning-Generosity (SL-Gen) Task: Redesigning the multi-round trust game paradigm to examine social learning and generosity sensitivity in young people
Social learning is important for societal functioning, and adolescence is a critical period for development and maintenance of social behaviors. Specifically, the ability to establish and maintain social interactions that are beneficial, while avoiding or removing oneself from social exchanges that are detrimental or harmful, is crucial for healthy interpersonal functioning. Beyond self-report measures, the multi-round trust game, a commonly used behavioral economics paradigm, has utility for elucidating differences in social decision-making between healthy and clinical populations. To more specifically probe the role of social learning and generosity sensitivity during social exchange in young people, we have designed a new task: the Social Learning-Generosity (SL-Gen) Task. Using versions of the multi-round trust game as a basis for the design, we have incorporated more environmentally realistic task components, including controlled gain, loss, and variable gain-loss generosity conditions. In a single-session online study, the present research investigated task behavior and task acceptability in individuals aged 18-24 from a United Kingdom census-based sample, as well as exploring task differences by self-reported trust and gender. While this task is sensitive to differences in self-reported trust and gender and behaves similarly to existing versions of the trust game with respect to these effects, it has added utility within mental health research and treatment contexts for characterizing social decision-making behavior in more detail using set generosity conditions.
- Open Access
The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers
Introduction: Cognitive flexibility, defined as the ability to shift mental strategies when environmental demands change, may influence psychological well-being and psychiatric treatment outcomes. Emerging research increasingly implicates the renin angiotensin system (RAS) in cognition, yet its role in cognitive flexibility is inadequately understood. Methods: We conducted a double-masked trial with N=60 healthy adults aged 18-50. Participants were randomly assigned to receive a single 50 mg dose of losartan, an angiotensin II receptor blocker, or placebo. Following a waiting period, participants completed a task-switching paradigm as a measure of cognitive flexibility, which required dynamically categorizing arrows based on location or direction. Statistical analyses were conducted to determine group (losartan vs. placebo), task (location vs. direction), and switch (switching vs. repeating a task) effects on reaction time (RT) and accuracy independently. A composite bin score was also computed, integrating both RT and accuracy data. Results: All participants displayed the expected switch costs. While participants on losartan exhibited numerically superior RTs and accuracy, losartan did not significantly improve task-switching performance relative to placebo. This was confirmed by the bin score analysis, which indicated no benefit of losartan when RT and accuracy were considered together. An exploratory probe suggested that losartan improved accuracy on direction switch trials, indicating a potential drug effect under specific cognitive conditions. Conclusion: Overall, we found no significant benefits of losartan on task-switching in healthy adults. Our results may be explained by ceiling effects in our sample, which could have hindered the detection of group differences, or possibly reflect a negligible role for the RAS in cognitive flexibility.
Open AccessThe renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers
Introduction: Cognitive flexibility, defined as the ability to shift mental strategies when environmental demands change, may influence psychological well-being and psychiatric treatment outcomes. Emerging research increasingly implicates the renin angiotensin system (RAS) in cognition, yet its role in cognitive flexibility is inadequately understood. Methods: We conducted a double-masked trial with N=60 healthy adults aged 18-50. Participants were randomly assigned to receive a single 50 mg dose of losartan, an angiotensin II receptor blocker, or placebo. Following a waiting period, participants completed a task-switching paradigm as a measure of cognitive flexibility, which required dynamically categorizing arrows based on location or direction. Statistical analyses were conducted to determine group (losartan vs. placebo), task (location vs. direction), and switch (switching vs. repeating a task) effects on reaction time (RT) and accuracy independently. A composite bin score was also computed, integrating both RT and accuracy data. Results: All participants displayed the expected switch costs. While participants on losartan exhibited numerically superior RTs and accuracy, losartan did not significantly improve task-switching performance relative to placebo. This was confirmed by the bin score analysis, which indicated no benefit of losartan when RT and accuracy were considered together. An exploratory probe suggested that losartan improved accuracy on direction switch trials, indicating a potential drug effect under specific cognitive conditions. Conclusion: Overall, we found no significant benefits of losartan on task-switching in healthy adults. Our results may be explained by ceiling effects in our sample, which could have hindered the detection of group differences, or possibly reflect a negligible role for the RAS in cognitive flexibility.
- Open Access
Early effects of a novel 5-HT 4 agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: the RESTAND study
Background: Selective serotonin reuptake inhibitors (SSRIs) are limited by inadequate response in a significant minority of patients, slow onset, minimal cognitive benefit, and side effects. Preclinical studies suggest selective serotonin 4 receptor (5-HT 4 R) agonists may produce faster antidepressant effects via distinct mechanisms, however there has been no experimental research in clinical populations to date. Aims: To test whether the novel 5-HT 4 R partial agonist PF-04995274 produces early behavioural and neural changes in emotional cognition similar to SSRIs in patients with unmedicated major depressive disorder (MDD). Method: In a double-blind, placebo-controlled trial, 90 participants with MDD were randomised to 7 days of PF-04995274 (15 mg), citalopram (20 mg), or placebo. Emotional processing was assessed using a behavioural facial expression recognition task and fMRI of implicit emotional face processing (days 6–9). Observer– and self-reported symptoms of depression were also measured at baseline and study end. Results: As anticipated, citalopram reduced accuracy and reaction time for negative faces, with corresponding fMRI changes (reduced left amygdala activation to emotional faces and valence-specific shifts in cortical regions). In contrast, PF-04995274 produced no change in behavioural negative bias or amygdala activity but increased medial-frontal cortex activation across valences. While this was not a clinical trial, both active treatments reduced observer-rated depression severity relative to placebo; PF-04995274 also reduced self-reported depression, state anxiety, and negative affect. No major adverse events occurred. Conclusions: PF-04995274 was not associated with the typical antidepressant profile of negative bias reductions seen with citalopram but was associated with distinct medial-frontal activation during an emotional faces task and displayed preliminary evidence of early clinical improvement, suggesting a potential alternative mechanism for antidepressant effects. Findings support further clinical trials of 5-HT4R agonists and investigation of pro-cognitive and mood effects. Clinicaltrials.gov registration number: NCT03516604. Data set information: Analysis scripts and selected data will be available on publication.
Open AccessEarly effects of a novel 5-HT 4 agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: the RESTAND study
Background: Selective serotonin reuptake inhibitors (SSRIs) are limited by inadequate response in a significant minority of patients, slow onset, minimal cognitive benefit, and side effects. Preclinical studies suggest selective serotonin 4 receptor (5-HT 4 R) agonists may produce faster antidepressant effects via distinct mechanisms, however there has been no experimental research in clinical populations to date. Aims: To test whether the novel 5-HT 4 R partial agonist PF-04995274 produces early behavioural and neural changes in emotional cognition similar to SSRIs in patients with unmedicated major depressive disorder (MDD). Method: In a double-blind, placebo-controlled trial, 90 participants with MDD were randomised to 7 days of PF-04995274 (15 mg), citalopram (20 mg), or placebo. Emotional processing was assessed using a behavioural facial expression recognition task and fMRI of implicit emotional face processing (days 6–9). Observer– and self-reported symptoms of depression were also measured at baseline and study end. Results: As anticipated, citalopram reduced accuracy and reaction time for negative faces, with corresponding fMRI changes (reduced left amygdala activation to emotional faces and valence-specific shifts in cortical regions). In contrast, PF-04995274 produced no change in behavioural negative bias or amygdala activity but increased medial-frontal cortex activation across valences. While this was not a clinical trial, both active treatments reduced observer-rated depression severity relative to placebo; PF-04995274 also reduced self-reported depression, state anxiety, and negative affect. No major adverse events occurred. Conclusions: PF-04995274 was not associated with the typical antidepressant profile of negative bias reductions seen with citalopram but was associated with distinct medial-frontal activation during an emotional faces task and displayed preliminary evidence of early clinical improvement, suggesting a potential alternative mechanism for antidepressant effects. Findings support further clinical trials of 5-HT4R agonists and investigation of pro-cognitive and mood effects. Clinicaltrials.gov registration number: NCT03516604. Data set information: Analysis scripts and selected data will be available on publication.
- Open Access
- 22 May 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e155
Effects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial
Background: Statins are among the most prescribed medications worldwide. Both beneficial (e.g. antidepressant and pro-cognitive) and adverse (e.g. depressogenic and cognitive-impairing) mental health outcomes have been described in clinical studies. The underlying neuropsychological mechanisms, whether positive or negative, are, however, not established. Clarifying such activities has implications for the safe prescribing and repurposing potential of these drugs, especially in people with depression. Methods: In this double-blind, randomized, placebo-controlled experimental medicine study, we investigated the effects of simvastatin on emotional processing, reward learning, working memory, and waking salivary cortisol (WSC) in 101 people at-risk for depression due to reported high loneliness scores (mean 7.3 ± 1.2 on the UCLA scale). This trial was largely conducted during periods of social distancing due to the COVID-19 pandemic (July 2021–February 2023), and we employed a fully remote design within a UK-wide sample. Results: High retention rates, minimal outlier data, and typical main effects of task condition (e.g. emotion) were seen in all cognitive tasks, indicating this approach was comparable to in-person testing. After 28 days, we found no statistically significant differences (F’s < 3.0, p’s > 0.20) for any of the measures of emotional processing, reward learning, working memory, and WSC. Conclusions: Study results do not substantiate concerns regarding adverse neuropsychiatric events due to statins and support the safety of their prescribing in at-risk populations. Although other unmeasured cognitive processes may be involved, our null findings are also in line with more recent clinical evidence suggesting statins do not show antidepressant or pro-cognitive efficacy.
- 22 May 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e155
Open AccessEffects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial
Background: Statins are among the most prescribed medications worldwide. Both beneficial (e.g. antidepressant and pro-cognitive) and adverse (e.g. depressogenic and cognitive-impairing) mental health outcomes have been described in clinical studies. The underlying neuropsychological mechanisms, whether positive or negative, are, however, not established. Clarifying such activities has implications for the safe prescribing and repurposing potential of these drugs, especially in people with depression. Methods: In this double-blind, randomized, placebo-controlled experimental medicine study, we investigated the effects of simvastatin on emotional processing, reward learning, working memory, and waking salivary cortisol (WSC) in 101 people at-risk for depression due to reported high loneliness scores (mean 7.3 ± 1.2 on the UCLA scale). This trial was largely conducted during periods of social distancing due to the COVID-19 pandemic (July 2021–February 2023), and we employed a fully remote design within a UK-wide sample. Results: High retention rates, minimal outlier data, and typical main effects of task condition (e.g. emotion) were seen in all cognitive tasks, indicating this approach was comparable to in-person testing. After 28 days, we found no statistically significant differences (F’s < 3.0, p’s > 0.20) for any of the measures of emotional processing, reward learning, working memory, and WSC. Conclusions: Study results do not substantiate concerns regarding adverse neuropsychiatric events due to statins and support the safety of their prescribing in at-risk populations. Although other unmeasured cognitive processes may be involved, our null findings are also in line with more recent clinical evidence suggesting statins do not show antidepressant or pro-cognitive efficacy.
- Open Access
- 23 December 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-8
Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow
PET and SPECT studies in treatment-resistant schizophrenia (TRS) have revealed significant alterations in regional cerebral blood flow (CBF) during clozapine treatment, which may vary according to the clinical response. Here, we used the more recent MRI approach of arterial spin labelling (ASL) to evaluate regional CBF in participants with TRS (N = 36) before starting treatment with clozapine compared to in healthy volunteers (N = 16). We then compared CBF in the TRS group, before and after 12 weeks of treatment with clozapine (N = 24); and examined the relationship of those differences against changes in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores over the treatment period. We observed widespread reductions in CBF in TRS compared to in healthy volunteers (p < 0.05). After covarying for global CBF and age, lower CBF in frontal and parietal regions was still evident (p < 0.05, FWE corrected). Clozapine treatment was associated with longitudinal decreases in CBF in the anterior cingulate cortex (ACC) (p < 0.05). Higher striatal CBF at baseline was associated with greater improvement in total and general symptoms following clozapine, and higher hippocampal CBF was associated with greater improvement in total and positive symptoms. Longitudinal reductions in CBF in the ACC and thalamus were associated with less improvement in negative (ACC), positive (thalamus), and total (thalamus) symptoms. These findings suggest that changes in CBF on clozapine administration in TRS may accompany symptomatic improvement, and that CBF prior to clozapine initiation may determine the degree of clinical response.
- 23 December 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-8
Open AccessResponse to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow
PET and SPECT studies in treatment-resistant schizophrenia (TRS) have revealed significant alterations in regional cerebral blood flow (CBF) during clozapine treatment, which may vary according to the clinical response. Here, we used the more recent MRI approach of arterial spin labelling (ASL) to evaluate regional CBF in participants with TRS (N = 36) before starting treatment with clozapine compared to in healthy volunteers (N = 16). We then compared CBF in the TRS group, before and after 12 weeks of treatment with clozapine (N = 24); and examined the relationship of those differences against changes in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores over the treatment period. We observed widespread reductions in CBF in TRS compared to in healthy volunteers (p < 0.05). After covarying for global CBF and age, lower CBF in frontal and parietal regions was still evident (p < 0.05, FWE corrected). Clozapine treatment was associated with longitudinal decreases in CBF in the anterior cingulate cortex (ACC) (p < 0.05). Higher striatal CBF at baseline was associated with greater improvement in total and general symptoms following clozapine, and higher hippocampal CBF was associated with greater improvement in total and positive symptoms. Longitudinal reductions in CBF in the ACC and thalamus were associated with less improvement in negative (ACC), positive (thalamus), and total (thalamus) symptoms. These findings suggest that changes in CBF on clozapine administration in TRS may accompany symptomatic improvement, and that CBF prior to clozapine initiation may determine the degree of clinical response.
- Open Access
- 27 September 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Longitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts
The second-generation antipsychotic clozapine is used as a medication for treatment-resistant schizophrenia. It has previously been associated with epigenetic changes in pre-clinical rodent models and cross-sectional studies of treatment-resistant schizophrenia. Cross-sectional studies are susceptible to confounding, however, and cannot disentangle the effects of diagnosis and medication. We therefore profiled DNA methylation in sequential blood samples (n = 126) from two independent cohorts of patients (n = 38) with treatment-resistant schizophrenia spectrum disorders who commenced clozapine after study enrolment and were followed up for up to six months. We identified significant non-linear changes in cell-type proportion estimates derived from DNA methylation data - specifically B-cells - associated with time on clozapine. Mixed effects regression models were used to identify changes in DNA methylation at specific sites associated with time on clozapine, identifying 37 differentially methylated positions (DMPs) (p < 5 × 10-5) in a linear model and 90 DMPs in a non-linear quadratic model. We compared these results to data from our previous epigenome-wide association study (EWAS) meta-analysis of psychosis, finding evidence that many previously identified DMPs associated with schizophrenia and treatment-resistant schizophrenia might reflect exposure to clozapine. In conclusion, our results indicate that clozapine exposure is associated with changes in DNA methylation and cellular composition. Our study shows that medication effects might confound many case-control studies of neuropsychiatric disorders performed in blood.
- 27 September 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Open AccessLongitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts
The second-generation antipsychotic clozapine is used as a medication for treatment-resistant schizophrenia. It has previously been associated with epigenetic changes in pre-clinical rodent models and cross-sectional studies of treatment-resistant schizophrenia. Cross-sectional studies are susceptible to confounding, however, and cannot disentangle the effects of diagnosis and medication. We therefore profiled DNA methylation in sequential blood samples (n = 126) from two independent cohorts of patients (n = 38) with treatment-resistant schizophrenia spectrum disorders who commenced clozapine after study enrolment and were followed up for up to six months. We identified significant non-linear changes in cell-type proportion estimates derived from DNA methylation data - specifically B-cells - associated with time on clozapine. Mixed effects regression models were used to identify changes in DNA methylation at specific sites associated with time on clozapine, identifying 37 differentially methylated positions (DMPs) (p < 5 × 10-5) in a linear model and 90 DMPs in a non-linear quadratic model. We compared these results to data from our previous epigenome-wide association study (EWAS) meta-analysis of psychosis, finding evidence that many previously identified DMPs associated with schizophrenia and treatment-resistant schizophrenia might reflect exposure to clozapine. In conclusion, our results indicate that clozapine exposure is associated with changes in DNA methylation and cellular composition. Our study shows that medication effects might confound many case-control studies of neuropsychiatric disorders performed in blood.